pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Ga
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
2215-CL-0201
Phase 3 · small molecule · Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
2215-CL-0201 for Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy is a Phase 3 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code 2215-CL-0201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Astellas Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
- Status
- active
- Trials
- 1